进行了一项回顾性队列研究，以检查老年患者基底细胞癌 (BCC) 的治疗。目的是根据虚弱程度和生存趋势确定可以最小化干预的亚组。所有年龄 90 岁及以上的患者均进行组织学检查。该研究纳入了 2017 年和 2018 年期间确诊的 BCC（n = 319）。年龄是最重要的生存预测因素（HR=1.10（95% CI：1.04-1.17）；p=0.001）。最大阈值分析确定 93 岁为重要的年龄分界点。 ≤93岁的中位生存期为40个月，>93岁的中位生存期为28个月（p=0.002）。患有痴呆症的患者比没有痴呆症的患者生存期更差（中位生存期分别为 25 个月和 35 个月；HR=1.92（95% CI：1.18-3.13）；p=0.009）。接受 BCC 治疗的患者 (n=294) 与观察患者 (n=25) 相比，生存率存在统计学显着差异（中位生存期分别为 34 个月与 21 个月；HR= 0.54（95% CI：0.34- 0.85）；p=0.007）。检查的所有其他合并症对生存没有影响。这项研究提供了支持对二级护理中年龄≥90岁的个体进行积极治疗BCC的证据。对于痴呆症患者或 93 岁以上的患者，保守治疗可能更可取。© 作者 2024。由牛津大学出版社代表英国皮肤科医师协会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

A retrospective cohort study was undertaken to examine the management of basal cell carcinoma (BCC) in older patients.The aim was to identify subgroups where intervention could be minimised, based on frailty and trends in survival.All patients aged 90 years and over with histologically confirmed BCC during 2017 and 2018 were included within the study (n = 319).Age was the most significant predictor of survival (HR=1.10 (95% CIs: 1.04-1.17); p=0.001). Maximum threshold analysis identified 93 years as the significant age cutpoint. Median survival was 40 months for ≤93 years and 28 months for >93 years (p=0.002). Patients with dementia had a worse survival than those without (median survival: 25 months versus 35 months, respectively; HR=1.92 (95% CIs: 1.18-3.13); p=0.009). There was a statistically significant difference in survival for patients who received treatment for their BCC (n=294) compared those observed (n=25) (median survival 34 months versus 21 months, respectively; HR= 0.54 (95% CIs: 0.34-0.85); p=0.007). All other comorbidities examined had no influence on survival.This study provides evidence in support of active treatment of BCC in individuals aged ≥90 years, seen in secondary care. Conservative options may be preferable in patients with dementia or those >93 years old.© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.